West Pharmaceutical Services (WST) EV to EBITDA (2009 - 2026)

West Pharmaceutical Services has disclosed EV to EBITDA across 18 years of filings, most recently posting 138.68 for Q2 2026.

• In Q2 2026, EV to EBITDA rose 40.03% year-over-year to 138.68; the TTM figure through Jun 2026 stood at 36.5 (up 39.48% YoY), while the FY2025 annual figure was 32.52, down 20.12% from the prior year.
• EV to EBITDA came in at 138.68 for Q2 2026 at West Pharmaceutical Services, up from 97.4 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 230.33 in Q1 2024 to a low of 93.88 in Q3 2022.
• Average EV to EBITDA over 5 years is 138.66, with a median of 142.02 recorded in 2026.
• Year-over-year, EV to EBITDA surged 61.41% in 2023 and tumbled 46.74% in 2025.
• Over 5 years, EV to EBITDA stood at 127.56 in 2022, then gained by 21.93% to 155.54 in 2023, then fell by 6.55% to 145.35 in 2024, then declined by 16.44% to 121.45 in 2025, then increased by 14.19% to 138.68 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 138.68 in Q2 2026, 97.4 in Q1 2026, and 121.45 in Q4 2025.